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Abstract
Introduction: Participation in antiretroviral therapy (ART) programmes has been associated with greater utilization of care for
hypertension and diabetes in rural South Africa. The objective of this study was to assess whether people living with HIV on
ART with comorbid hypertension or diabetes also have improved chronic disease management indicators.
Methods: The Health and Aging in Africa: a longitudinal study of an INDEPTH Community in South Africa (HAALSI) is a
cohort of 5059 adults >40 years old. Enrollment took place between November 2014 and November 2015. The study col-
lected population-based data on demographics, healthcare utilization, height, weight, blood pressure (BP) and blood glucose as
well as HIV infection, HIV-1 RNA viral load (VL) and ART exposure. We used regression models to determine whether HIV
care cascade stage (HIV-negative, HIV+ /No ART, ART/Detected HIV VL, and ART/Undetectable VL) was associated with diag-
nosis or treatment of hypertension or diabetes, and systolic blood pressure and glucose among those with diagnosed hyper-
tension or diabetes. ART use was measured from drug level testing on dried blood spots.
Results and discussion: Compared to people without HIV, ART/Undetectable VL was associated with greater awareness of
hypertension diagnosis (adjusted risk ratio (aRR) 1.18, 95% CI: 1.09 to 1.28) and treatment of hypertension (aRR 1.24, 95%
CI: 1.10 to 1.41) among those who met hypertension diagnostic criteria. HIV care cascade stage was not significantly associ-
ated with awareness of diagnosis or treatment of diabetes. Among those with diagnosed hypertension or diabetes, ART/Unde-
tectable VL was associated with lower mean systolic blood pressure (5.98 mm Hg, 95% CI: 9.65 to 2.32) and lower mean
glucose (3.77 mmol/L, 95% CI: 6.85 to 0.69), compared to being HIV-negative.
Conclusions: Participants on ART with an undetectable VL had lower systolic blood pressure and blood glucose than the HIV-
negative participants. HIV treatment programmes may provide a platform for health systems strengthening for cardiometabolic
disease.
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1 | INTRODUCTION
As HIV-positive populations age in the era of widespread
antiretroviral therapy (ART) availability, there is an urgent
need to better understand the biological and health systems
implications of the growing burden of cardiometabolic disease
among people living with HIV (PLWH) [1-3]. This is especially
true for resource-limited health systems in sub-Saharan Africa
that face large HIV epidemics and a growing prevalence of
diabetes and hypertension among adults [4]. A better under-
standing of the intersection between HIV and cardiometabolic
conditions such as diabetes and hypertension offers a
potential avenue for health systems strengthening, as care
programmes that have been established for PLWH may pro-
vide a ready platform for the response to non-communicable
diseases. Leveraging the overlap between HIV and car-
diometabolic care programmes, and aligning both with efforts
to expand universal health coverage, has the promise of
improving population health for all [5,6].
Research at the nexus of these epidemics has been limited
to date, in part due to scant sources of data that include
information about both HIV and cardiometabolic conditions in
the same participants [7]. However, several studies have
demonstrated both good feasibility and high levels of uptake
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when screening for multiple chronic diseases – including HIV,
diabetes and hypertension – is implemented through an inte-
grated health campaign [8,9]. Moreover, a recent study con-
ducted in a rural South African cohort showed that
participants in ART programmes have greater frequency of
diagnosis and lifestyle counselling for both diabetes and
hypertension as well as greater awareness of diagnosis and
treatment for hypertension, compared to HIV-negative partici-
pants [10]. The objective of this study was to assess whether
PLWH on ART with co-morbid hypertension or diabetes also
have improved chronic disease management indicators.
2 | METHODS
2.1 | Data collection
This study was conducted using baseline data from Health
and Aging in Africa: a longitudinal study of an INDEPTH Com-
munity in South Africa (HAALSI). HAALSI is a cohort of adults
aged 40 and over based in the Agincourt sub-district of rural
South Africa [11,12]. Participants in HAALSI were randomly
sampled from the Agincourt Health and Demographic Surveil-
lance Site (HDSS). Enrollment took place from November
2014 to November 2015 [13,14]. The baseline survey was
administered by local fieldworkers and participant responses
recorded in a Computer-Assisted Personal Interview system
[15]. The study collected self-reported demographic and eco-
nomic characteristics as well as measures of healthcare utiliza-
tion for HIV, diabetes and hypertension. Anthropometry, blood
pressure, point-of-care glucose and dried blood spots (DBS)
were also collected at the time of the survey. Participants pro-
vided consent for participation in the survey and dried blood
spot collection.
Dried blood spots were tested for HIV using the Vironos-
tika HIV 1/2 Ag/Ab MicroELISA System (BioMerieux, Marcy
l’Etoile, France) and the Roche Cobas E411 Combi Ag (India-
napolis, IN, USA) respectively. We tested for HIV-1 RNA using
the BioMerieux NucliSens, which had a lower limit of detec-
tion of <100 copies/mL. All participants with a positive HIV
antibody test also had a subsequent viral load (VL) test.
To ascertain whether patients with a positive HIV test were
receiving ART, all participants with a positive HIV test were
subsequently tested for exposure to emtricitabine (FTC) and
lamivudine (3TC) using DBS. Testing was done at the Univer-
sity of Cape Town using high performance liquid chromatogra-
phy which detected the presence of either drug at
concentrations down to 0.02 lg/mL [16]. This concentration
detects use of either drug within the past 1.5 days.
2.2 | Statistical analyses
Our primary predictor of interest is a categorical HIV status
descriptor comprised of HIV serostatus, recent ART use and
virologic suppression. Participants were defined as one of the
following: (1) HIV-negative; (2) HIV-positive but not currently
using ART (HIV-positive/No ART); (3) HIV-positive with recent
ART use but with a detectable VL (ART/Detected VL); or (4)
HIV-positive participants with an undetectable VL (ART/Unde-
tectable VL). Those participants who had an undetectable VL
were considered to be in the ART/Undetectable VL even if
their ART assay was negative.
Our outcomes of interest were as follows: (1) awareness of
a hypertension diagnosis; (2) treatment of hypertension
among those who meet criteria for diagnosis of hypertension
(3) mean systolic blood pressure among those who meet crite-
ria for a diagnosis of hypertension; (4) awareness of diabetes
diagnosis; (5) treatment of diabetes among those who meet
criteria for a diagnosis of diabetes and (6) blood glucose mea-
surement among those who meet criteria for a diagnosis of
diabetes. We defined a diagnosis of hypertension as any of
the following: (1) a mean systolic blood pressure ≥140 mm
Hg; (2) a mean diastolic blood pressure ≥90 mm Hg; (3) a
self-reported diagnosis of hypertension that had been made
by a doctor, nurse or healthcare worker; or (4) self-reported
use of medication for hypertension prescribed by a doctor
nurse or healthcare worker. We defined a diagnosis of dia-
betes as any of the following: (1) a fasting glucose ≥7.0 mmol/
L; (2) a random plasma glucose ≥11.1 mmol/L; (3) a self-
reported diagnosis of diabetes that had been made by a doc-
tor, nurse or healthcare worker; or (4) self-reported use of
medication for diabetes prescribed by a doctor, nurse or
healthcare worker [13,17,18].
We used log-binomial regression models to examine the
association between diagnosis and treatment of hypertension
or diabetes and stage in the HIV care cascade. These models
were adjusted for age, sex, BMI, education and wealth quintile.
We then fit linear regression models, also adjusted for age,
sex, BMI, education and wealth quintile, to estimate differ-
ences in mean systolic blood pressure and blood glucose by
stage in the HIV care cascade. We additionally adjusted the
blood glucose model for fasting status. We then fit linear
regression models including the entire population and second,
excluding those with a BMI < 18.5, to minimize the possibility
of confounding between HIV treatment and blood pressure or
glucose due to advanced HIV disease stage. We used one-way
ANOVA to test for differences in means and chi-squared tests
to compare proportions. All statistical analyses were con-
ducted in STATA v. 14 (College Station, TX, USA).
2.3 | Ethics statement
This study received ethics approval from the University of
Witwatersrand (#M141159), the Harvard T.H. Chan School of
Public Health (#13-1608), and the Mpumalanga Provincial
Research and Ethics Committee.
3 | RESULTS AND DISCUSSION
Our analytic sample included 4547 participants who had an
HIV antibody test result and where applicable, ART exposure
data available. Further details about participation in the
HAALSI cohort are available elsewhere [10]. The HIV-negative
participants were significantly older than the HIV-positive par-
ticipants. There were no differences in the sex distribution
across groups but mean BMI and the percentage who were
overweight or obese decreased from the HIV negative to the
HIV positive/No ART and ART/Detected VL groups, then
increased slightly in the ART/Undetectable VL group.
(Table 1)
In multivariable-adjusted log binomial models, we found a
significant relationship between being ART/Undetectable VL
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and awareness of hypertension diagnosis (adjusted risk ratio
(aRR): 1.18, 95% CI: 1.09 to 1.28) and treatment of hyperten-
sion (aRR 1.24, 95% CI: 1.10 to 1.41) among those who met
criteria for a diagnosis of hypertension, compared to those
who were HIV negative. There were no significant relation-
ships between stage in the HIV care cascade and receipt of
diagnosis (aRR 1.14, 95% CI: 0.88 to 1.47) or treatment (aRR
1.04, 95% CI: 0.71 to 1.51) for diabetes (Tables S1 to S3).
In multivariable-adjusted linear regression models among
those with diagnosed hypertension or diabetes, the ART/
Undetectable VL group had a lower mean systolic BP
(5.98 mm Hg, 95% CI: 9.65 to 2.32) and lower mean
glucose (3.77 mmol/L, 95% CI: 6.85 to 0.69), compared
to the HIV-negative participants (see Figure 1). This effect
was preserved when excluding those who were underweight,
where being in the ART/Undetectable VL stage of the HIV
care cascade was associated with a 5.94 mm Hg (95% CI:
9.68 to 2.20) decrease in blood pressure and 3.74 mmol/L
(95% CI: 6.89 to 0.59) decrease in blood glucose as
compared to the HIV-negative group. The complete results of
these regression analyses are provided in the Supporting
Information (Table S1). We also provide results of a model of
blood glucose restricted to only the non-fasting population, in
which our finding is preserved (Table S1).
In a community-based study of individuals in rural South
Africa, we found, among individuals with hypertension and dia-
betes, PLWH who had an undetectable VL were more likely to
be aware of and treated for a comorbid diagnosis of hyperten-
sion, and, among those who were diagnosed with hypertension
or diabetes, they also had lower mean blood pressure and
blood glucose than their HIV-negative counterparts. These
findings are relevant to health systems in countries such as
South Africa, which have large HIV epidemics and robust ART
programmes, because it provides preliminary evidence that
the HIV care platform may be leveraged to improve primary
healthcare delivery for other chronic conditions [10]. This find-
ing is a critical extension of prior research in this cohort
demonstrating greater self-reported service utilization among
Table 1. Demographic and health characteristics across the HIV care cascade in the HAALSI cohort, 2015
HIV negative HIV positive/No ART ART/detected VL ART/undetected VL p
Total 3512 301 183 551 —
Age (mean) 63.6 54.4 55.6 55.9 <0.001
Age 40 to 49 504 (14.4) 113 (37.5) 44 (24.0) 148 (26.9) <0.001
Age 50 to 59 870 (24.8) 98 (32.6) 81 (44.3) 206 (37.4)
Age 60 to 69 959 (27.3) 60 (19.9) 43 (23.5) 141 (25.6)
Age 70 to 79 719 (20.5) 24 (8.0) 13 (7.1) 51 (9.3)
Age 80+ 460 (13.1) 6 (2.0) 2 (1.1) 5 (0.9)
Sex (%) 1898 (54.0) 168 (55.8) 94 (51.4) 298 (54.1) 0.823
Education <0.001
<1 year 1,660 (47.4) 130 (43.3) 70 (38.7) 226 (41.1)
One to five years 1225 (35.0) 90 (30.0) 62 (34.3) 204 (37.1)
Six to seven years 345 (9.8) 52 (17.3) 29 (16.0) 79 (14.4)
Eight plus years 272 (7.8) 28 (9.4) 20 (11.0) 41 (7.4)
BMI class (%) <0.001
Underweight 160 (4.8) 21 (7.2) 17 (9.7) 37 (6.9)
Normal 1133 (34.0) 129 (44.3) 83 (47.2) 235 (44.0)
Overweight 971 (29.2) 68 (23.4) 44 (25.0) 145 (27.2)
Obese 1064 (32.0) 73 (25.0) 32 (18.2) 117 (21.9)
Wealth quintile
Quintile 1 695 (19.8) 90 (29.9) 42 (23.0) 120 (21.8)
Quintile 2 700 (19.9) 62 (20.6) 39 (21.3) 112 (20.3)
Quintile 3 679 (19.3) 56 (18.6) 39 (21.3) 118 (21.4)
Quintile 4 695 (19.8) 48 (16.0) 36 (19.7) 111 (20.2)
Quintile 5 743 (21.2) 45 (15.0) 27 (14.8) 90 (16.3)
Hypertensiona (%) 2394 (68.4) 143 (47.7) 84 (45.9) 255 (46.4) <0.001
Diabetesb (%) 446 (12.9) 21 (7.1) 11 (6.0) 48 (8.8) <0.001
ART, antiretroviral therapy.
aHypertension was defined as any of the following: (1) a mean systolic blood pressure ≥140 mm Hg or (2) a mean diastolic blood pressure
≥90 mm Hg or (3) a self-reported diagnosis of hypertension that had been made by a doctor, nurse or healthcare worker or (4) self-reported use
of medication for hypertension prescribed by a doctor nurse or healthcare worker. bDiabetes was defined as any of the following: (1) a fasting
plasma glucose ≥7.0 mmol/L; (2) a random plasma glucose ≥11.1 mmol/L; (3) a self-reported diagnosis of diabetes that had been made by a doc-
tor, nurse or healthcare worker; or (4) self-reported use of medication for diabetes prescribed by a doctor, nurse or healthcare worker.
Manne-Goehler J et al. Journal of the International AIDS Society 2019, 22:e25213
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25213/full | https://doi.org/10.1002/jia2.25213
3
those with well-controlled HIV on ART, because it shows that
chronic disease management indicators may also be improved
among those with HIV who are also virally suppressed
on ART and thus suggests that PLWH with comorbid car-
diometabolic disease may fare better in the health system
than their HIV-negative counterparts. Further efforts to inte-
grate care for HIV and other chronic diseases may offer an
avenue to improve outcomes for all. For instance, in Uganda,
several studies have demonstrated high rates of acceptance of
community-based integrated screening for HIV alongside dia-
betes, hypertension and malaria. In one study, they showed
that as many as 95% of women and 52% of men were willing
to participate in integrated campaigns [8,9]. In South Africa,
integration of care is already beginning to be pursued through
the Ideal Clinics initiative [19].
Although further data are required to establish the mecha-
nisms for this relationship, one plausible hypothesis is that
the greater frequency and intensity of contact afforded to
ART users provides secondary health gains. For example,
most people in HIV care see healthcare providers, counsel-
lors, and pharmacists every two to three months, which may
increases opportunities for diagnosis, health education, and
treatment of other common comorbid diseases of HIV.
Another possible explanation for this finding is that those
who have an undetectable VL on ART have greater health lit-
eracy or are more likely to be adherent to health advice and
medical therapies, and thus have better blood pressure and
glycaemic control in the setting of comorbid hypertension or
diabetes. Other alterative explanations may include HIV or
ART-specific effects on blood pressure or glucose, survivor-
ship bias, or other unmeasured confounders. We attempted
to mitigate the blood pressure and glucose lowering-effects
of advanced HIV reported elsewhere [20-23] by conducting
analyses restricted to people with a normal, overweight or
obese BMI. Moreover, our population-based study design
additionally minimizes confounding by allowing inclusion of
PLWH at all stages of the treatment cascade, as opposed to
a clinic-based population, which might bias estimation to
those with health-seeking behaviours.
There are several limitations to this study. First, we rely on
cross-sectional data, and thus cannot establish causality [24].
This study is meant to advance hypothesis generation about
the spillover effects of ART programmes for other chronic dis-
ease states. However, further investigation is needed to con-
firm these findings in longitudinal data and to test the
effectiveness of various models of integrated care on both
HIV and cardiometabolic disease outcomes over time. Second,
our study had a small numbers of participants with diabetes,
which limited our ability to make definitive conclusions
about relationships between HIV and utilization of diabetes
care. Third, we have a small sample size in the ART/
Detected VL group so it is difficult to interpret whether
ART programmes are also improving care for diabetes and
hypertension in this strata of participants. Finally, there is
the possibility of misclassification of ART use status as we
assign the ART use categories primarily through an assay
that detects a drug with a short half-life. As such, it is pos-
sible that a participant may be classified as “not on ART”
when they are on ART but have recently skipped doses.
We attempt to overcome any misclassification of ART use
status by including those who are virally suppressed but do
not have ART detected in their blood in “ART/Undetectable”
group.
4 | CONCLUSION
In summary, this study supports a potential to harness ART
programmes to strengthen systems of care for other HIV-
associated cardiometabolic conditions. More research is
needed to assess the causal pathways underlying these rela-
tionships, and determine optimal models of care for integrated
management of these conditions.
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Figure 1. Predictive mean systolic blood pressure (BP) and glucose among those with diagnosed hypertension or diabetes by HIV Care Cas-
cade Group in the HAALSI cohort, 2015.
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